Form 8-K VERTEX PHARMACEUTICALS For: Jul 25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Vertex (VRTX) PT Raised to $203 at RBC Capital
July 26, 2018 8:44 AM EDTRBC Capital raised its price target on Vertex (NASDAQ: VRTX) to $203.00 (from $202.00) while maintaining an Outperform rating.
Analyst Brian Abrahams commented, "Despite rising expectations into 2Q, an impressive beat for VRTX's CF franchise."
... MoreVertex (VRTX) PT Raised to $204 at BMO Capital; 'Stellar Revenue'
July 26, 2018 7:11 AM EDTBMO Capital raised its price target on Vertex (NASDAQ: VRTX) to $204.00 (from $191.00) while maintaining an Outperform rating following results.
Analyst Do Kim commented, "We raise our revenue estimates and target price to $204 from $191, following stellar 2Q18 CF revenues that easily exceeded our and... More
